<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="22%"></colgroup><colgroup width="12%"></colgroup><colgroup span="2" width="22%"></colgroup> <tbody> <tr> <td class="subtitle1">Author, year</td> <td class="subtitle1">Country</td> <td class="subtitle1">n</td> <td class="subtitle1">Chemotherapy</td> <td class="subtitle1">Hazard ratio for survival (95% CI)</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Non-anthracycline-containing polychemotherapy</td> </tr> <tr> <td class="indent1">Huguier M; 1980</td> <td>France</td> <td>53</td> <td>5-FU, VBL, CTX</td> <td>No significant survival difference</td> </tr> <tr> <td class="indent1">Schlag P; 1982</td> <td>Germany</td> <td>98</td> <td>5-FU, BCNU</td> <td>0.66 (0.31-1.41)</td> </tr> <tr> <td class="indent1">Douglass H; 1982</td> <td>USA</td> <td>142</td> <td>5-FU, MeCCNU</td> <td>0.58 (0.35-0.95)*</td> </tr> <tr> <td class="indent1">Ochiai T; 1983</td> <td>Japan</td> <td>59</td> <td>MMC, 5-FU, Ara-C</td> <td>1.08 (0.5-2.31)</td> </tr> <tr> <td class="indent1">Higgins G; 1983</td> <td>USA</td> <td>134</td> <td>5-FU, MeCCNU</td> <td>0.94 (0.58-1.53)</td> </tr> <tr> <td class="indent1">Engstrom P; 1985</td> <td>USA</td> <td>180</td> <td>5-FU, MeCCNU</td> <td>0.94 (0.58-1.53)</td> </tr> <tr> <td class="indent1">Jakesz R; 1988</td> <td>Austria</td> <td>87</td> <td>Ara-C, MMC, 5-FU</td> <td>0.65 (0.38-1.13)</td> </tr> <tr> <td class="indent1">Bonfanti G; 1988</td> <td>Italy</td> <td>144</td> <td>5-FU, MeCCNU</td> <td>0.97 (0.61-1.55)</td> </tr> <tr> <td class="indent1">Allum W; 1989</td> <td>UK</td> <td>271</td> <td>MMC, 5-FU</td> <td>0.99 (0.73-1.36)</td> </tr> <tr> <td class="indent1">Allum W; 1989</td> <td>UK</td> <td>270</td> <td>CTX, 5-FU, VCR, MTX<sup>¶</sup> then MMC, 5-FU</td> <td>1.01 (0.74-1.38)</td> </tr> <tr> <td class="indent1">Nakajima T; 1999</td> <td>Japan</td> <td>573</td> <td>MMC, 5-FU, UFT</td> <td>0.74 (0.5-1.09)</td> </tr> <tr> <td class="indent1">Cirera L; 1999</td> <td>Spain</td> <td>148</td> <td>MMC, Ftorafur</td> <td>0.60 (0.39-0.93)*</td> </tr> <tr> <td class="indent1">Nashimoto A; 2003</td> <td>Japan</td> <td>252</td> <td>MMC, 5-FU, Ara-C</td> <td>No significant survival difference</td> </tr> <tr class="divider_bottom"> <td class="indent1">Bang Y; 2012</td> <td>Korea</td> <td>1035</td> <td>Capecitabine, oxaliplatin</td> <td>0.72 (0.52-1.00)*</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Anthracycline-containing polychemotherapy</td> </tr> <tr> <td class="indent1">Coombes R; 1990</td> <td>UK</td> <td>281</td> <td>5-FU, DOX, MMC</td> <td>0.89 (0.66-1.21)</td> </tr> <tr> <td class="indent1">Krook J; 1991</td> <td>USA</td> <td>125</td> <td>5-FU, DOX</td> <td>0.97 (0.62-1.51)</td> </tr> <tr> <td class="indent1">Hallissey M; 1994</td> <td>UK</td> <td>283</td> <td>5-FU, DOX, MMC</td> <td>0.95 (0.74-1.22)</td> </tr> <tr> <td class="indent1">Macdonald J; 1995</td> <td>USA</td> <td>193</td> <td>5-FU, DOX, MMC</td> <td>0.91 (0.65-1.28)</td> </tr> <tr> <td class="indent1">Lise M; 1995</td> <td>Italy</td> <td>294</td> <td>5-FU, DOX, MMC</td> <td>0.86 (0.64-1.14)</td> </tr> <tr> <td class="indent1">Tsavaris N; 1996</td> <td>Greece</td> <td>84</td> <td>5-FU, EPI, MMC</td> <td>0.76 (0.31-1.87)</td> </tr> <tr> <td class="indent1">Neri B; 1996</td> <td>Italy</td> <td>103</td> <td>5-FU, LV, EPI</td> <td>0.46 (0.27-0.77)*</td> </tr> <tr> <td class="indent1">Di Costanzo F; 2008</td> <td>Italy</td> <td>258</td> <td>PELF</td> <td>0.91 (0.64-1.26)</td> </tr> <tr> <td class="indent1">Bouche O; 2005</td> <td>France</td> <td>260</td> <td>Infusional 5-FU, CIS</td> <td>0.74 (0.54-1.02)</td> </tr> <tr> <td class="indent1">Nitti D; 2006</td> <td>EORTC</td> <td>206</td> <td>5-FU, DOX, MTX</td> <td>0.89 (0.51-1.31)<sup>Δ</sup></td> </tr> <tr> <td class="indent1">Nitti D; 2006</td> <td>ICCG</td> <td>191</td> <td>5-FU, EPI, MTX</td> <td>1.05 (0.69-1.41)<sup>Δ</sup></td> </tr> <tr> <td class="indent1">De Vita F; 2007</td> <td>GOIM</td> <td>228</td> <td>5-FU, LV, EPI, ETOP</td> <td>0.91 (0.69-1.21)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Kulig J; 2010</td> <td>Poland</td> <td>309</td> <td>EAP</td> <td>0.889 (0.676-1.169)</td> </tr> <tr> <td class="subtitle2_left" colspan="5">S-1 monotherapy</td> </tr> <tr> <td class="indent1">Sasako M; 2011</td> <td>Japan</td> <td>1059</td> <td>S-1</td> <td>0.67 (0.54-0.83)*</td> </tr> </tbody></table></div><div class="graphic_footnotes">5-FU: fluorouracil; VBL: vinblastine; CTX: cyclophosphamide; BCNU: Carmustine; MeCCNU: Semustine (methyl-CCNU); MMC: mitomycin C; Ara-C: cytarabine; MTX: methotrexate; VCR: vincristine; UFT: ftorafur and uracil; DOX: doxorubicin; EPI: epirubicin; LV: leucovorin; PELF: cisplatin, epirubicin, leucovorin, 5-FU; CIS: cisplatin; EORTC: European Organization for Research and Treatment of Cancer; ICCG: International Collaborative Cancer Group; GOIM: Grupopa Oncologico dell'Italia Meridionale; ETOP: etoposide; EAP: etoposide, doxorubicin, cisplatin.<br/>* Statistically significant values for survival.<br/>¶ Induction chemotherapy with five days of CTX, 5-FU, VCR, and MTX, followed by MMC and 5-FU.<br/>Δ Both trials reported together, neither of which reached its accrual goal (760 for the EORTC and 480 for the ICCG trials).</div><div id="graphicVersion">Graphic 71898 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
